The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Ophthalmic Disease Therapeutic Market Research Report 2025
Synopsis
Global Ophthalmic Disease Therapeutic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ophthalmic Disease Therapeutic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ophthalmic Disease Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Regeneron Pharmaceuticals
AbbVie Inc
Santen Pharmaceutical Co. Ltd.
Novartis AG
Bayer AG
F. Hoffmann-La Roche
Viatris Inc.
Segment by Type
Anti-inflammatory
Anti-infectives
Anti-VEGF
Anti-glaucoma
Segment by Application
Glaucoma
Dry Eye Disease
Retinal Diseases
Allergy & Infections
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Ophthalmic Disease Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Global Ophthalmic Disease Therapeutic market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Ophthalmic Disease Therapeutic market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Ophthalmic Disease Therapeutic market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Regeneron Pharmaceuticals
AbbVie Inc
Santen Pharmaceutical Co. Ltd.
Novartis AG
Bayer AG
F. Hoffmann-La Roche
Viatris Inc.
Segment by Type
Anti-inflammatory
Anti-infectives
Anti-VEGF
Anti-glaucoma
Segment by Application
Glaucoma
Dry Eye Disease
Retinal Diseases
Allergy & Infections
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Ophthalmic Disease Therapeutic report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ophthalmic Disease Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anti-inflammatory
1.2.3 Anti-infectives
1.2.4 Anti-VEGF
1.2.5 Anti-glaucoma
1.3 Market by Application
1.3.1 Global Ophthalmic Disease Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Glaucoma
1.3.3 Dry Eye Disease
1.3.4 Retinal Diseases
1.3.5 Allergy & Infections
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ophthalmic Disease Therapeutic Market Perspective (2018-2029)
2.2 Ophthalmic Disease Therapeutic Growth Trends by Region
2.2.1 Global Ophthalmic Disease Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ophthalmic Disease Therapeutic Historic Market Size by Region (2018-2023)
2.2.3 Ophthalmic Disease Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Ophthalmic Disease Therapeutic Market Dynamics
2.3.1 Ophthalmic Disease Therapeutic Industry Trends
2.3.2 Ophthalmic Disease Therapeutic Market Drivers
2.3.3 Ophthalmic Disease Therapeutic Market Challenges
2.3.4 Ophthalmic Disease Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ophthalmic Disease Therapeutic Players by Revenue
3.1.1 Global Top Ophthalmic Disease Therapeutic Players by Revenue (2018-2023)
3.1.2 Global Ophthalmic Disease Therapeutic Revenue Market Share by Players (2018-2023)
3.2 Global Ophthalmic Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ophthalmic Disease Therapeutic Revenue
3.4 Global Ophthalmic Disease Therapeutic Market Concentration Ratio
3.4.1 Global Ophthalmic Disease Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ophthalmic Disease Therapeutic Revenue in 2022
3.5 Ophthalmic Disease Therapeutic Key Players Head office and Area Served
3.6 Key Players Ophthalmic Disease Therapeutic Product Solution and Service
3.7 Date of Enter into Ophthalmic Disease Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ophthalmic Disease Therapeutic Breakdown Data by Type
4.1 Global Ophthalmic Disease Therapeutic Historic Market Size by Type (2018-2023)
4.2 Global Ophthalmic Disease Therapeutic Forecasted Market Size by Type (2024-2029)
5 Ophthalmic Disease Therapeutic Breakdown Data by Application
5.1 Global Ophthalmic Disease Therapeutic Historic Market Size by Application (2018-2023)
5.2 Global Ophthalmic Disease Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Ophthalmic Disease Therapeutic Market Size (2018-2029)
6.2 North America Ophthalmic Disease Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ophthalmic Disease Therapeutic Market Size by Country (2018-2023)
6.4 North America Ophthalmic Disease Therapeutic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ophthalmic Disease Therapeutic Market Size (2018-2029)
7.2 Europe Ophthalmic Disease Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ophthalmic Disease Therapeutic Market Size by Country (2018-2023)
7.4 Europe Ophthalmic Disease Therapeutic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ophthalmic Disease Therapeutic Market Size (2018-2029)
8.2 Asia-Pacific Ophthalmic Disease Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ophthalmic Disease Therapeutic Market Size by Region (2018-2023)
8.4 Asia-Pacific Ophthalmic Disease Therapeutic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ophthalmic Disease Therapeutic Market Size (2018-2029)
9.2 Latin America Ophthalmic Disease Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ophthalmic Disease Therapeutic Market Size by Country (2018-2023)
9.4 Latin America Ophthalmic Disease Therapeutic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ophthalmic Disease Therapeutic Market Size (2018-2029)
10.2 Middle East & Africa Ophthalmic Disease Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ophthalmic Disease Therapeutic Market Size by Country (2018-2023)
10.4 Middle East & Africa Ophthalmic Disease Therapeutic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Detail
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Ophthalmic Disease Therapeutic Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 AbbVie Inc
11.2.1 AbbVie Inc Company Detail
11.2.2 AbbVie Inc Business Overview
11.2.3 AbbVie Inc Ophthalmic Disease Therapeutic Introduction
11.2.4 AbbVie Inc Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.2.5 AbbVie Inc Recent Development
11.3 Santen Pharmaceutical Co. Ltd.
11.3.1 Santen Pharmaceutical Co. Ltd. Company Detail
11.3.2 Santen Pharmaceutical Co. Ltd. Business Overview
11.3.3 Santen Pharmaceutical Co. Ltd. Ophthalmic Disease Therapeutic Introduction
11.3.4 Santen Pharmaceutical Co. Ltd. Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.3.5 Santen Pharmaceutical Co. Ltd. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Ophthalmic Disease Therapeutic Introduction
11.4.4 Novartis AG Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.4.5 Novartis AG Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Ophthalmic Disease Therapeutic Introduction
11.5.4 Bayer AG Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.5.5 Bayer AG Recent Development
11.6 F. Hoffmann-La Roche
11.6.1 F. Hoffmann-La Roche Company Detail
11.6.2 F. Hoffmann-La Roche Business Overview
11.6.3 F. Hoffmann-La Roche Ophthalmic Disease Therapeutic Introduction
11.6.4 F. Hoffmann-La Roche Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.6.5 F. Hoffmann-La Roche Recent Development
11.7 Viatris Inc.
11.7.1 Viatris Inc. Company Detail
11.7.2 Viatris Inc. Business Overview
11.7.3 Viatris Inc. Ophthalmic Disease Therapeutic Introduction
11.7.4 Viatris Inc. Revenue in Ophthalmic Disease Therapeutic Business (2018-2023)
11.7.5 Viatris Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
